Trans-Diamminedichloroplatinum (II) Is Not an Antitumor Drug: Why?

  • Rozenn Dalbiès
  • Marc Boudvillain
  • Marc Leng


The clinical activity of the antitumor drug cis-diamminedichloroplatinum(II) (cis-DDP) is thought to be related to its ability to form bifunctional lesions in DNA. trans-Diamminedichloroplatinum(II) (trans-DDP), the stereoisomer of cis-DDP, is clinically ineffective, although it forms bifunctional cross-links in the in vitro reaction with DNA1–4. A question still unsolved is why only cis-DDP is an antitumor drug.


Central Sequence Linkage Isomerization Dinuclear Platinum Metal Coordination Compound Monofunctional Adduct 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    A. Eastman, The formation, isolation and characterization of DNA adducts produced by anticancer platinum complexes, Pharmacol Ther., 34, 155–166 (1987).CrossRefPubMedGoogle Scholar
  2. 2.
    S. L. Bruhn, J. H. Toney, and S. J. Lippard, Biological processing of DNA modified by platinum compounds, in “Progress in Inorganic Chemistry: Bioinorganic Chemistry”, S. J. Lippard, ed., Wiley, New York (1990).Google Scholar
  3. 3.
    J. Reedijk, The relevance of hydrogen bonding in the mechanism of action of platinum antitumor compounds, Inorg. Chim. Acta, 198: 873 (1992).CrossRefGoogle Scholar
  4. 4.
    M. Sip and M. Leng, DNA, cis-platinum and intercalators: catalytic activity of the DNA double helix, in “Nucleic Acids and Molecular Biology” (vol. 7), F. Eckstein and D. M. J. Lilley, eds., Springer, Berlin (1993).Google Scholar
  5. 5.
    A.L. Pinto and S. J. Lippard, Sequence-dependent termination of in vitro DNA synthesis by cis- and trans-diamminedichloroplatinum(II), Proc. Natl. Acad. Sci. U.S. A., 82: 4616 (1985).CrossRefPubMedGoogle Scholar
  6. 6.
    A. Eastman and M. A. Barry, Interactions of trans-diamminedichloroplatinum(II) with DNA: formation of monofunctional adducts and their reaction with glutathione, Biochemistry, 26: 3303 (1987).CrossRefPubMedGoogle Scholar
  7. 7.
    A. Eastman, M. M. Jennerwein and D. L. Nagel, Characterization of bifunctional adducts produced in DNA by trans-diamminedichloroplatinum(II), Chem. Biol. Interact, 67: 71 (1988).CrossRefPubMedGoogle Scholar
  8. 8.
    M.F. Anin and M. Leng, Distortions induced in double-stranded oligonucleotides by the binding of cis- and trans-diamminedichloroplatinum(II) to the d(GTG) sequence, Nucleic Acids Res., 18: 4395 (1990).CrossRefPubMedGoogle Scholar
  9. 9.
    C. A. Lepre, L. Chassot, C. E. Costello, and S. J. Lippard, Synthesis and characterization of tarns-[Pt(NH3)2Cl2] adducts of d(CCTCGAGTCTCC). d(GGAGACTCGAGG), Biochemistry, 29: 811 (1990).CrossRefPubMedGoogle Scholar
  10. 10.
    K. M. Comess, C. E. Costello, and S. J. Lippard, Identification and characterization of a novel linkage isomerization in the reaction of trans-diamminedichloroplatinum(II) with 5′-d(TCTACGCGTTCT), Biochemistry, 29: 2102 (1990).CrossRefPubMedGoogle Scholar
  11. 11.
    R. Dalbiès, D. Payet, and M. Leng, DNA double helix promotes a linkage isomerization reaction in trans-diamminedichloroplatinum(II) modified DNA, Proc. Natl Acad Sci. U.S.A., 91: 8147 (1994).CrossRefPubMedGoogle Scholar
  12. 12.
    A. Eastman, Characterization of the adducts produced in DNA by cis-diamminedichloroplatinum(II) and cis-dichloro(ethylenediamine) platinum(II), Biochemistry, 22: 3927 (1983).CrossRefPubMedGoogle Scholar
  13. 13.
    A. M. Fichtinger-Shepman, J. L. Van der Veer, P. H. Lohman, and J. Reedijk, Adducts of the antitumor drug cis-diamminedichloroplatinum(II) with DNA: formation, identification and quantitation, Biochemistry, 24: 707 (1985).CrossRefGoogle Scholar
  14. 14.
    D. Payet, F. Gaucheron, M. Sip, and M. Leng, Instability of the monofunctional adducts in cis-[Pt(NH3)2(N7-N-methyl-2-diazapyrenium)Cl]2+-modified DNA: rates of cross-linking reactions in cis-platinum-modified DNA, Nucleic Acids Res., 21: 5846(1993).CrossRefPubMedGoogle Scholar
  15. 15.
    R. G. Wilkins, The deduction of mechanisms, in “Kinetics and Mechanism of Reactions of Transition Metal Complexes” (2nd ed.), VCH, Weinhem, Germany (1991).CrossRefGoogle Scholar
  16. 16.
    J. M. Malinge, A. Schwartz, and M. Leng, Characterization of the ternary complexes formed in the reaction of cis-diamminedichloroplatinum(II), ethidium bromide and nucleic acids, Nucleic Acids Res., 15: 1779 (1987).CrossRefPubMedGoogle Scholar
  17. 17.
    R. Rahmouni, A. Schwartz, and M. Leng, Importance of DNA sequence in the reaction of d(ApG) and d(GpA) with cis-diamminedichloroplatinum(II), in “Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy”, S. B. Howell, ed., Plenum Press, New-York (1988).Google Scholar
  18. 18.
    N. J. Rampino and V. A. Bohr, Rapid gene-specific repair of cisplatin lesions at the human DUG/DHFR locus comprising the divergent upstream gene and dihydrofolate reductase gene during early G1 phase of the cell cycle assayed by using the exonucleolytic activity of T4 DNA polymerase, Proc. Nail. Acad. Sci. U.S.A., 91: 10977 (1994).CrossRefGoogle Scholar
  19. 19.
    Y. Zou, B. Van Houten, and N. Farrell, Sequence specificity of DNA-DNA interstrand cross-links formation by cisplatin and dinuclear platinum complexes, Biochemistry, 33: 5404 (1994).CrossRefPubMedGoogle Scholar
  20. 20.
    V. Brabec and M. Leng, DNA interstrand cross-links of trans-diamminedichloroplatinum(II) are preferentially formed between guanine and complementary cytosine residues, Proc. Natl. Acad. Sci. U.S.A., 90: 5345 (1993).CrossRefPubMedGoogle Scholar
  21. 21.
    R. Dalbiès, M. Boudvillain, and M. Leng, Linkage isomerization reaction of intrastrand cross-links in trans-diamminedichloroplatinum(II)-modified single-stranded oligonucleotides, Nucleic Acids Res. (in press).Google Scholar
  22. 22.
    M. Boudvillain, R. Dalbiès, and M. Leng, Rearrangement of the 1,3-intrastrand crosslinks into interstrand cross-links in transplatinum-modified DNA (submitted for publication).Google Scholar
  23. 23.
    M. A. Lemaire, A. Schwartz, A. R. Rahmouni, and M. Leng, Interstrand cross-links are preferentially formed at the d(GC) sites in the reaction between cis-diamminedichloroplatinum(II) and DNA, Proc. Natl. Acad. Sci. U.S.A. 88: 1982 (1991).CrossRefPubMedGoogle Scholar
  24. 24.
    U. Belluco, Substitution reactions, in “Organometallic and coordination Chemistry of Platinum”, Academic Press, London (1974).Google Scholar
  25. 25.
    D. P. Bancroft, C. A. Lepre, and S. J. Lippard, 195Pt NMR kinetic and mechanistic studies of cis- and trans-diamminedichloroplatinum(II) binding to DNA, J. Am. Chem. Soc., 112: 6860 (1990).CrossRefGoogle Scholar
  26. 26.
    F. Gaucheron, J. M. Malinge, A. J. Blacker, J. M. Lehn, and M. Leng, Possible Catalytic activity of DNA in the reaction between the antitumor drug cis-diamminedichloroplatinum(II) and the intercalator N-methyl-2,7-diazapyrenium, Proc. Natl. Acad Sci. U.S.A., 88: 3516 (1991).CrossRefPubMedGoogle Scholar
  27. 27.
    D. Payet and M. Leng, DNA, cisplatinum and heterocyclic amines: catalytic activity of the DNA double helix, in “Structural Biology: The State of the Art”, R. H. Sarma and M. H. Sarma, eds, Adenine, Guilderland, NY (1994).Google Scholar
  28. 28.
    C. Hélène and J. J. Toulmé, Specific regulation of gene expression by antisense, sense and anti-gene nucleic acids, Biochim. Biophys. Acta, 1049: 99 (1990).CrossRefPubMedGoogle Scholar
  29. 29.
    W. S. Marshall and M. H. Caruthers, Phosphorothioate DNA as a potential therapeutic drug, Science, 259: 1564 (1993).CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1996

Authors and Affiliations

  • Rozenn Dalbiès
    • 1
  • Marc Boudvillain
    • 1
  • Marc Leng
    • 1
  1. 1.Centre de Biophysique MoleculaireCNRSOrleans Cedex 2France

Personalised recommendations